---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-006708"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:22:05.948425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated

## Summary
- Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.
- Pharmacokinetic analysis showed linear dose-plasma relationship; intranasal route suggests greater brain delivery.
- Company plans to proceed to Phase II trials, working with FDA and U.S. military for site identification and study design.
- Concussion treatment global market valued at $6.9B (2020), forecast $8.9B by 2027.

## SEC filing metadata
- accession: 0001683168-22-006708
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822006708/0001683168-22-006708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822006708/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-006708
- JSON: https://secwatch.observer/filing/0001683168-22-006708.json
- Plain text: https://secwatch.observer/filing/0001683168-22-006708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.